PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.04%
Negative revenue growth while 2127.T stands at 58.10%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.96%
Negative gross profit growth while 2127.T is at 80.79%. Joel Greenblatt would examine cost competitiveness or demand decline.
-21.69%
Negative EBIT growth while 2127.T is at 123.57%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.23%
Negative operating income growth while 2127.T is at 130.18%. Joel Greenblatt would press for urgent turnaround measures.
-22.15%
Negative net income growth while 2127.T stands at 122.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.17%
Negative EPS growth while 2127.T is at 121.69%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.17%
Negative diluted EPS growth while 2127.T is at 121.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 2127.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.54%
10Y revenue/share CAGR 1.25-1.5x 2127.T's 39.83%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
56.54%
5Y revenue/share CAGR 1.25-1.5x 2127.T's 39.83%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
56.54%
3Y revenue/share CAGR 1.25-1.5x 2127.T's 39.83%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
152.46%
Net income/share CAGR above 1.5x 2127.T's 90.37% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
152.46%
5Y net income/share CAGR above 1.5x 2127.T's 90.37%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
152.46%
3Y net income/share CAGR above 1.5x 2127.T's 90.37%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
81.73%
Equity/share CAGR of 81.73% while 2127.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
81.73%
Equity/share CAGR of 81.73% while 2127.T is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
81.73%
Equity/share CAGR of 81.73% while 2127.T is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.71%
Inventory growth of 16.71% while 2127.T is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
4.66%
Asset growth well under 50% of 2127.T's 16.94%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.59%
50-75% of 2127.T's 9.93%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-11.84%
We’re deleveraging while 2127.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.